BioCryst Pharmaceuticals, Inc.

NASDAQ: BCRX
$9.05
+$0.25 (+2.8%)
Closing price May 26, 2022
Friday's top analyst upgrades and downgrades included AppLovin, BioCryst Pharmaceuticals, Boeing, CF Industries, Coupa Software, Crocs, Dutch Bros, DigitalOcean, Gilead Sciences, IBM, International...
Monday’s additional top analyst upgrades and downgrades included Aptiv, BioCryst Pharmaceuticals, CSX, Gap, Nektar Therapeutics, Progressive, Peloton Interactive, Sirius XM and United Airlines.
Monday's top analyst upgrades and downgrades included Alibaba, AT&T, Baidu, Bilbili, CommScope, JetBlue Airways, Navient, Nvidia, Pinduoduo, Schlumberger, Sea, State Street, Truist Financial, U.S....
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Tuesday, including Affirm, BioCryst Pharmaceuticals, Exxon Mobile, First Solar and Tesla.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including BioCryst, Editas, Groupon, Sunrun, Twitter and more.
Ford, General Electric and these other stocks are likely to survive the current troubles and could very well offer patient investors some huge returns over the next year or so.
Tuesday's top analyst upgrades and downgrades included AppFolio, BioCryst Pharmaceuticals, Booking, DraftKings, Intuit, L Brands, Peloton Interactive, Salesforce.com and Wells Fargo.
As with almost all pandemic scares and other national and global issues, some speculative stocks manage to see their shares rise sharply.
The Wuhan Coronavirus has escaped China, with the number of cases and the death toll rising. The economic impact beyond the loss of life and suffering is real in many stocks, sectors and local...
The Wuhan Coronavirus has already left China and hit neighboring countries, the U.S. and even in Europe in Australia. As the death toll and number of infected are rising each hour, the economic...
BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients.
Every week we search for stocks covered by top Wall Street analysts that are trading under the $10 level and could provide solid upside potential. This week we found five companies covered by...
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
BioCryst Pharmaceuticals shares fell on Tuesday after the company announced initial results from its hereditary angioedema trial.
The top analyst upgrades, downgrades and other research calls from Tuesday include Applied Materials, BioCryst, Costco, Generac, Goodyear, Intel, Microsoft and Netflix.